Utility of cystatin C as a marker for the severity of aortic regurgitation in hypertensive patients.
Cystatin C, a cathepsin inhibitor, is involved in the remodeling of human aortic valve and left ventricle (LV). Cystatin C may be related to the severity of aortic regurgitation (AR). We measured cystatin C and CRP in hypertensive patients with mild-to-moderate AR (n=120) and in those without AR (n=128). Echocardiography was performed to assess the vena contracta width (the narrowest region of regurgitant jet, VCW) as a marker of the severity of AR, relative wall thickness as a marker of LV concentric remodeling, and the ratio of early peak mitral flow to early diastolic mitral annular velocity (E/e') as an index of LV diastolic function. Glomerular filtration rate (GFR) was estimated using the MDRD methods. Cystatin C levels were greater in hypertensive patients with AR than in those without AR. A multiple linear regression analysis indicated cystatin C levels correlated with the VCW independent of GFR, body mass index, CRP, relative wall thickness, and E/e' in hypertensive patients with AR. Cystatin C was associated with the severity of regurgitation independent of renal function body composition chronic inflammation LV remodeling and diastolic function in hypertensive patients with mild-to-moderate AR.